Fresenius Medical Care AG (NYSE:FMS) Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management decreased its position in Fresenius Medical Care AG (NYSE:FMS) by 44.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 20,374 shares of the company’s stock after selling 16,527 shares during the period. Ritholtz Wealth Management’s holdings in Fresenius Medical Care were worth $434,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Fresenius Medical Care by 21.8% in the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after buying an additional 758 shares in the last quarter. ORG Partners LLC acquired a new position in Fresenius Medical Care during the first quarter worth about $110,000. SageView Advisory Group LLC purchased a new stake in shares of Fresenius Medical Care in the first quarter valued at about $127,000. Signaturefd LLC grew its position in shares of Fresenius Medical Care by 8.4% in the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after purchasing an additional 672 shares during the last quarter. Finally, Kimelman & Baird LLC purchased a new position in shares of Fresenius Medical Care during the 2nd quarter worth approximately $186,000. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $20.03 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The firm has a market cap of $11.75 billion, a PE ratio of 22.51, a P/E/G ratio of 1.06 and a beta of 0.91. The firm has a 50 day simple moving average of $19.92 and a 200-day simple moving average of $20.05. Fresenius Medical Care AG has a 1-year low of $16.37 and a 1-year high of $22.76.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The company had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. On average, equities analysts expect that Fresenius Medical Care AG will post 1.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on FMS. Truist Financial upped their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. StockNews.com initiated coverage on Fresenius Medical Care in a research report on Tuesday, October 8th. They issued a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.